Skip to main content
Equibles
HRMY logo

HRMY · Harmony Biosciences Holdings, Inc. · Metrics

Track HRMY — free

Use HRMY with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research HRMY.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$41.62 -0.45 (-1.07%) At close · Sep 9
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$2.45B
Shares
58.24M

HRMY metrics

83 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$41.62
Market cap
$2.45B

Price action

20 metrics
Price change (1W)
+2.0%
Price change (30D)
+7.9%
Price change (3M)
+23.4%
Price change (6M)
+46.4%
Price change (YTD)
+12.4%
Price change (1Y)
+17.4%
Trailing year
Price change (5Y)
+9.2%
52-week high
$42.86
52-week low
$25.90
Change from 52-week high
-1.8%
Change from 52-week low
+62.4%
Annualized volatility
44.6%
Annualized volatility (3M)
43.9%
Beta
0.6
RSI (14D)
64.5
Price vs SMA 50
+11.6%
Price vs SMA 200
+22.8%
Avg volume (3M)
837,264
Relative volume
2.1
Average dollar volume
$30.99M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
58.24M

Valuation

12 metrics
P / E (TTM)
13.7
Trailing earnings · reciprocal yield 7.3%
PEG ratio
0.2
EV / revenue
2.0×
reciprocal yield 49.5%
EV / EBITDA
—
EV / EBIT
8.4×
reciprocal yield 11.9%
P / sales
2.6×
reciprocal yield 39.1%
P / book
2.5
reciprocal yield 40.7%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
6.9
reciprocal yield 14.5%
Earnings yield
7.4%

Historical valuation

8 metrics
P / E historical average (3Y)
13.1×
reciprocal yield 7.6%
P / E historical average (5Y)
20.5×
reciprocal yield 4.9%
EV / revenue historical average (3Y)
2.2×
reciprocal yield 46.2%
EV / revenue historical average (5Y)
4.0×
reciprocal yield 25.0%
EV / EBIT historical average (3Y)
7.8×
reciprocal yield 12.8%
EV / EBIT historical average (5Y)
14.4×
reciprocal yield 6.9%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-04

Profitability

9 metrics
Gross margin
75.4%
Operating margin
24.0%
Trailing 12 months
Net margin
18.9%
Gross profit (TTM)
$723.99M
Operating profit (TTM)
$230.65M
Net income (TTM)
$181.27M
Trailing 12 months
Diluted EPS (TTM)
$3.08
FCF margin
—
Effective tax rate
24.8%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$15.07

Growth

11 metrics
Revenue growth YoY
+30.3%
Year over year
Net income growth YoY
+89.6%
Revenue (TTM)
$959.90M
Trailing 12 months
EPS growth YoY
+88.2%
Shares change YoY
+0.6%
Year over year · more shares
Revenue CAGR (3Y)
+25.6%
Revenue CAGR (5Y)
+40.3%
EPS CAGR (3Y)
-3.0%
EPS CAGR (5Y)
—
FCF CAGR (3Y)
+34.1%
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
18.1%
Return on assets
13.2%
Debt / equity
0.2
Current ratio
3.5
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
3.5
Interest coverage
17.1
Net debt / EBITDA
—
Return on invested capital
35.7%
Trailing 12 months
Net cash
$513.83M
Latest balance sheet
Cash & equivalents
$549.77M
Total assets
$1.37B
Total debt
$153.96M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$355.08M
Capital expenditures (TTM)
$310,000
R&D (TTM)
$220.87M
SG&A (TTM)
—
Stock compensation (TTM)
$40.90M
R&D / revenue
23.0%
Stock compensation / revenue
4.3%

Ownership (13F)

3 metrics
13F filers
330
13F filer change QoQ
+16
Institutional ownership
93.7%

Short interest

3 metrics
Short interest
7.1%
Latest settlement · 4.8 days to cover
Days to cover
4.8d
Short-squeeze score
64 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$1.45M
Insider-sentiment score
34 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1802665 CUSIP 413197104 13F (30d) 199 filings 198 filers Visit website Investor relations